On April 26, 2022 Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, reported that it will host an R&D Symposium to provide an update on the Company’s three clinical programs (Press release, Corvus Pharmaceuticals, APR 26, 2022, View Source [SID1234612966]). The event will be held on Tuesday, May 10, 2022, in New York City from 9:00 – 11:30 am Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D symposium will cover the Company’s pipeline programs: anti-CD73 (mupadolimab), adenosine 2A receptor antagonist (ciforadenant), and an update on ITK inhibitor (CPI-818) in T cell lymphomas. It will be hosted by Corvus President and CEO Richard A. Miller, M.D., and will include speakers from Corvus as well as leading researchers:

Neel K. Gupta, M.D., Clinical Assistant Professor of Medicine at Stanford University School of Medicine – Division Oncology
Suresh Mahabhashyam, M.D., Vice President of Clinical Development at Corvus Pharmaceuticals
Erik Verner, Ph.D., Senior Vice President of Research at Angel Pharmaceuticals
The symposium will be webcast live from Corvus’s website at www.corvuspharma.com and the replay will be available for 90 days following the event.